Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Advancements in Neurodegenerative Diseases: Pathogenesis and Novel Neurorestorative Interventions Publisher



Gao W1 ; Jing S2 ; He C3 ; Saberi H4 ; Sharma HS5 ; Han F6 ; Chen L2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Center for Beijing Neurorestoratologic Industry Innovation, Institute of Beijing Neurorestoratologic Industry Innovation, Beijing, 100041, China
  2. 2. Department of Neurosurgery, Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine, Beijing, 100007, China
  3. 3. Department of Neurosurgery, Zhuji Affiliated Hospital of Wenzhou Medical University, Zhejiang, Zhuji, 311800, China
  4. 4. Department of Neurosurgery, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, 1419733141, Iran
  5. 5. International Experimental Central Nervous System Injury & Repair (IECNSIR), Department of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, Frodingsgatan 12, LGH 1103, Uppsala, 75185, Sweden
  6. 6. Liaocheng University/Liaocheng People's Hospital, Institute for Tissue Engineering and Regenerative Medicine/Key Translational Laboratory of Stem Cell & Regenerative Medicine, Health Commission of Shandong Province, Shandong, Liaocheng, 252000, China

Source: Journal of Neurorestoratology Published:2025


Abstract

Progressive neurodegenerative diseases (NDs) that lack effective disease-modifying treatments, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD), represent significant global health challenges. In recent years, key research findings have included the role of neuroinflammation driven by microglia and astrocytes, the impact of genetic mutations, and the importance of autophagy and mitochondrial quality control in maintaining neuronal health. In this review, we summarize recent advancements of the pathogenesis of NDs, the cellular and animal models that have provided valuable insights into disease mechanisms, and the development of blood-based biomarkers for early diagnosis and monitoring of disease progression. We also highlight emerging neurorestorative therapeutic strategies involving stem cell therapy, antisense oligonucleotides, and induced pluripotent stem cells. Additionally, we cover recent clinical trials of promising drugs, such as lecanemab and donanemab for AD, and tavapadon for PD. Finally, we propose future research directions, emphasizing the need for combination therapies that target multiple pathways, the development of more precise animal models, and the integration of nanotechnology for improved drug delivery across the blood–brain barrier. © 2024